Clinical use of immunoglobulin titers of anti-cytomegalovirus antibodies

The frequency and severity of CMV infections in kidney, bone marrow, heart transplant recipients, in polytransfused patients, in immunodeficiencies and in newborns with congenital or peri-natal infection prompted clinical trials of immunoglobulins (Ig) with anti-CMV activity. Among the various methods for titrating Ig of plasmatic or placental origin, polyvalent or hyperimmune, ELISA would be the most sensitive assay and the neutralizing reaction might be the better reflection of a protective effect. In kidney transplantation, two non-randomized clinical trials have suggested a curative effect in association to other treatments, especially when given early. In bone marrow transplantation, three randomized studies have shown a prophylactic effect on incidence of symptomatic infections, interstitial pneumonias due to CMV, but only in seronegative patients not treated with leucocyte transfusions. No effect was observed on the time of infection, the survival of patients, the incidence of surinfections or graft versus host disease. The prophylactic effect of anti-CMV Ig in kidney and heart transplantation as well as in newborns has still to be documented in randomized trials. The possible clinical benefit for the patients and the mode of preparation of effective anti-CMV antibodies need further investigations.     

Effect of antibodies to glial glycolipid antigens on miniature endplate potentials

No more than 4% of the miniature endplate potentials (MEPP) recorded in preparations of frog cutaneous pectoral muscle kept in Ringers solution or treated with nonimmune rabbit serum were atypical, having a normal amplitude but abnormally retarded (almost doubled) time course. The percentage of atypical MEPP more than tripled after processing preparations with galactocerebroside (GalC) antiserum. Armine-induced blockade of synaptic acetylcholinesterase increased the rate of "giant" MEPP occurrence (but not of those with normal amplitude plus protracted time course). Mechanisms possibly underlying the increased percentage of atypical MEPP during GalC action on Schwann cells are discussed.I. P. Pavlov Institute of Physiology, Academy of Sciences of the USSR, Leningrad. Translated from Neirofiziologiya, Vol. 21, No. 2, pp. 217–223, March–April, 1989.     

Increased titers of antibodies to bifidobacteria as a marker of intestinal dysbacteriosis

The study showed that a high titer of antibodies to bifidobacteria can serve as a laboratory sign of intestinal dysbacteriosis.Translated from Fiziologiya Cheloveka, Vol. 31, No. 2, 2005, pp. 132–134.Original Russian Text Copyright © 2005 by Anikhovskaya, Vyshegurov, Likhoded, Yakovlev.     

Binding of soybean agglutinin to glycolipid components of porcine lymphocyte plasma membranes

¹²⁵I-Labeled soybean agglutinin binds primarily to glycolipids contained in pig lymphocyte plasma membranes as measured by in situ “staining” of membranes subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Separation of these glycolipids by differential extraction, silicic acid chromatography, and high-performance thin-layer chromatography showed that three different species of plasma membrane glycolipid bind this lectin; trihexosyl ceramide, globoside, and ganglioside G_M2 in order of increasing affinity (over a range of 10- to 20-fold). Trihexosyl ceramide and globoside, major neutral membrane glycolipids, are the major binders; while G_M2, a minor acidic glycolipid, is a quantitatively smaller lectin-binding component.     

Detection of red cell aggregation by low shear rate viscometry in whole blood with elevated plasma viscosity

The viscosity of whole blood measured at low shear rates is determined partly by shear resistance of the red cell aggregates present, stronger aggregation increasing the viscosity in the absence of other changes. Effects of cell deformability can confound interpretation and comparison in terms of aggregation, however, particularly when the plasma viscosity is high. We illustrate the problem with a comparison of hematocrit-adjusted blood from type 1 diabetes patients and controls in which it is found the apparent and relative viscosities at a true shear rate of 0.20 s-1 are lower in the patient samples than age matched controls, in spite of reports that aggregation is increased in such populations. Because the plasma viscosities of the patients were higher on average than controls, we performed a series of experiments to examine the effect of plasma protein concentration and viscosity on normal blood viscosity. Dilution or concentration by ultrafiltration of autologous plasma and viscosity measurements at low shear on constant hematocrit red cell suspensions showed (a) suspension viscosity at 0.25 and 3 s-1 increased monotonically with plasma protein concentration and viscosity but (b) the relative viscosity increased, in concert with the microscopic aggregation grade, up to a viscosity of approximately 1.25 mPa-s but above this the value the relative viscosity no longer increased as the degree of aggregation increased in concentrated plasmas. It is suggested that in order to reduce cell deformation effects in hyperviscous pathological plasmas, patient and control plasmas should be systematically diluted before hematocrit is adjusted and rheological measurements are made. True shear rates should be calculated. Comparison of relative viscosities at low true shear rates appears to allow the effects of red cell aggregation to be distinguished by variable shear rate viscometry in clinical blood samples.     

Leb-active glycolipid in human plasma: Measurement by radioimmunoassay

A radioimmunoassay that measures Le^b-active glycolipids in human plasma has been developed using antiserum from a goat immunized with a Le^b blood group hapten, lacto-N-difucohexaose I, conjugated to polylysine. Binding by the antiserum of lacto-N-difucohexaose I conjugated to ¹²⁵I-labeled bovine serum albumin is specifically inhibited by Le^b-active ceramide hexasaccharide. Plasma levels of the glycolipid are quantitated by comparing the inhibitory activity of plasma with that of the purified Le^b-active glycolipid. Plasma samples from 35 blood group O Le(a ? b +) individuals contain Le^b-active ceramide hexasaccharide at an average concentration of 0.9 μg/ml (range: 0.2 to 2.5 μg/ml); no Le^b-active glycolipid (less than 0.02 μg/ml) could be detected in plasma from blood group O Le(a + b?) or O Le(a? b?) individuals. Plasma from A₁ Le(a ? b+) individuals contains less Le^b-active glycolipid than plasma from A₂ Le(a? b+) individuals: its level in 19 samples of A, Le(a? b+) plasma averages 0.2 μg/ml (range: 0.1 to 0.45 μg/ml), and its level in 9 samples of A₂ Le(a? b+) plasma averages 1.1 μg/ml (range 0.8 to 1.3 μg/ml). About one-third of the total Le^b-active glycolipid in whole blood is associated with erythrocytes and the rest is found in plasma.     

The effects of soy protein in women and men with elevated plasma lipids

Fifty four postmenopausal women with elevated cholesterol were recruited for a randomised, double-blind controlled trial of soy protein containing isoflavones. (ISP+) or a soy protein with a low isoflavone content (ISP-), taken daily for 12 weeks. There was an overall reduction after 12 weeks in total cholesterol (TC), LDL cholesterol (LDL-C), sex hormone binding globulin (SHBG), and luteinizing hormone (LH). There were no significant differences between treatment groups. In a separate study 27 male subjects with a TC > 5.5 mmol/l were given ISP+ for 12 weeks. In this male study there was a significant increase in HDL cholesterol (HDL-C) and SHBG. Soy protein has a cholesterol lowering effect in both women and men. These studies suggest that this effect is independent of isoflavones. Soy protein also reduces SHBG levels in both sexes.     

Rational method of producing sera with high titers of virus neutralizing antibodies]

A possibility of obtaining the diagnostic specific sera with a high titre against the poliovirus, type I, was studied experimentally. Five different immunization schemes by the same antigen were tested in parallel experiments. A method of the viral antigen (both of the concentrated and of the unconcentrated) mixed with complete Freund's adjuvant injection into the popliteal lymph nodes with the subsequent single reimmunization proved to be most effective. In this way it was possible to obtain type-specific sera with a high titre (1:20 000--1:40 000) in the course of five weeks.     

Preparation of monoclonal antibodies against a glycolipid asialo GM1

Five IgM monoclonal antibodies (MAbs), MW-1, MW-2, MW-3, MW-4, and MW-5, against a glycolipid asialo GM1 were prepared from hybridoma clones obtained by the fusion of mouse NS-1 myeloma cells with spleen cells from a mouse immunized with asialo GM1 adsorbed to naked Salmonella. All the MAbs reacted only with asialo GM1 when their reactivities were examined by enzyme-linked immunosorbent assay (ELISA) and thin-layer chromatography (TLC)-immunostaining using structurally related glycolipids. The MAbs showed a complement-dependent lysis of mouse natural killer (NK) cells, but the lytic activities were weaker than that of a rabbit polyclonal anti-asialo GM1 antibody. When they were mixed, the anti-NK activity was increased to a level almost comparable to that of the polyclonal antibody. These results suggest that all the MAbs obtained are specific for asialo GM1 and that they may be different in fine specificity for the glycolipid. Significance of the MAbs in immunological and neurochemical studies is discussed.     

Specific antibodies to viruses HL-23 and BILN in the blood plasma of patients with acute myelogenous leukaemia and with potential preleukaemia

Blood plasma samples from patients with acute myelogenous leukaemia (AML) or potential preleukaemia and from control subjects were tested for antibodies to the viruses HL-23 and BILN by membrane immunofluorescence. Of 15 patients with untreated AML, three, each having a low peripheral leucocyte count at the time of sampling, had detectable antibodies. Antibodies were present in the plasma of 5 out of 8 AML patients being in remission as a result of chemotherapy. In these cases, the antibody levels significantly exceeded those demonstrated in the untreated cases. Of 12 patients with potential preleukaemia, five proved to be positive. Of the 7 antibody-negative patients, four developed manifest leukaemia within 12-18 months after the first testing. The results are suggestive of a favourable prognostic role of the presence of the antibodies under study. In the majority of the antibody-positive AML and potential preleukameia cases antibodies were detectable to both components of the HL-23 virus. Of 30 control subjects, three had demonstrable antibodies to the BILN virus.     

The use of recombinant antibodies in proteomics

Recombinant antibodies are becoming increasingly important in the field of proteomics. Recent advances include the development of large phage-antibody libraries that contain high-affinity binders to almost any target protein, and new methods for high-throughput selection of antibody-antigen interactions. Coupled with a range of new screening technologies that use high-density antibody arrays to identify differentially expressed proteins, these antibody libraries can be applied to whole proteome analysis.